New Antibody Treatment Targets Pancreatic Cancer
Scientists have developed a promising new antibody treatment that enhances the immune system’s ability to recognize and combat pancreatic cancer. This cancer is notorious for using a sugary “disguise” that helps it evade detection by the immune system.
While most current cancer therapies focus on proteins or genes, this innovative treatment targets the sugars present on the surface of cancer cells. Researchers from Northwestern University in Chicago discovered that blocking these sugars allows immune cells to find and attack the cancer effectively.
Dr. Mohamed Abdel-Mohsen, a senior author on the study, explained, “Pancreatic cancer is exceptionally good at hiding from the immune system. We were surprised to find that a single sugar called sialic acid can deeply mislead immune cells.” When tumors coat themselves with this sugar, they effectively send a ‘do not attack’ signal to the immune system.
In mouse studies, this therapy proved successful in inhibiting the sugar signal, resulting in a noticeable slowdown in cancer growth. Mice that received the antibody treatment had tumors that grew significantly slower than those that did not.
Encouraged by these findings, researchers are hopeful for potential tests in human populations. They believe this antibody treatment could work well alongside existing chemotherapy and immunotherapies.
The research was published in the journal Cancer Research on November 3. Dr. Abdel-Mohsen pointed out that while this is initial research and not a treatment ready for patients yet, it highlights a new immune target for fighting pancreatic cancer.
Dr. Heloisa P. Soares, an expert who did not participate in the study, found the results encouraging and noted, “It was surprising to see that a protein responsible for keeping cells together is also being used by pancreatic cancer as a hidden signal to avoid immune attack.”
Despite the optimistic findings, pancreatic cancer remains one of the deadliest cancers, often diagnosed at advanced stages and with a five-year survival rate of only about 13%. It’s particularly challenging to treat because it typically does not respond well to immunotherapy and tends to be diagnosed late due to a lack of symptoms.
The study’s lead researcher mentioned the limitations of the current animal testing, stating that it cannot capture the full complexity of human pancreatic cancer. Still, they believe this strategy could be part of multiple approaches to treat the disease effectively.
Experts emphasize the need for further clinical trials to evaluate the safety and effectiveness of this treatment in humans. Following successful trials, it may take about five years before this therapy could be available to patients.
In summary, while this new antibody treatment shows promise, experts caution that it is still in early stages, and further research is vital to make significant advancements in the fight against pancreatic cancer.
